Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication
Status:
Recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
This study have as primary aim "To compare the H. pylori eradication rate between the
quadruple bismuth therapy versus the standard triple therapy recommended by the AUGE Clinical
Guidelines for Helicobacter pylori eradication treatment in peptic ulcer patients."
Briefly, this is a randomized, multicenter, controlled, double-blind clinical trial with two
parallel arms. The control group will receive the current Standard Triple Therapy for the
eradication of H. pylori. It consists of omeprazole + amoxicillin + clarithromycin for 14
days. The intervention group will be administered Quadruple Therapy with Bismuth, which
consists in esomeprazole + amoxicillin + metronidazole + bismuth subsalicylate for 14 days